Management of Gut Motility Disorders

First-Line Prokinetic Agents

The American Gastroenterological Association recommends prokinetic medications, such as prucalopride, metoclopramide, domperidone, erythromycin, or octreotide, as the primary treatment for improving gut motility in patients with gastrointestinal motility disorders 1, 2
Prucalopride, a highly specific serotonin 5-HT4 receptor agonist, stimulates colonic peristalsis and enhances bowel motility, with a better cardiac safety profile than older 5-HT4 agonists 3
Metoclopramide, a combined dopamine antagonist and cholinergic agonist, can improve gut motility, particularly in the upper GI tract, but should be used with caution due to potential neurological side effects 1, 2
Erythromycin, a motilin agonist, can be beneficial in patients with absent or impaired antroduodenal migrating complexes, with a recommended dose of 900 mg/day, although tachyphylaxis can occur with continued use 3, 4
Octreotide, a somatostatin analogue, may be dramatically beneficial in patients with systemic sclerosis-associated chronic intestinal pseudo-obstruction (CIPO), with a prokinetic effect occurring at a subcutaneous dose of 50-100 μg once or twice daily 1, 5, 4

The European Society for Clinical Nutrition and Metabolism recommends dietary modifications, including fractionated intake divided into five to six small meals per day, a low-lactose, low-fiber, low-fat diet, and associated multivitamin and micronutrient supplementation, to optimize gut motility and decrease the risk of bacterial overgrowth 1, 8
A first-line pharmacological approach with prokinetics, such as prucalopride, metoclopramide, domperidone, erythromycin, or octreotide, is recommended, with consideration of combination therapy for enhanced effect 1, 2, 5, 4

The American Gastroenterological Association recommends avoiding surgery in CIPO patients whenever possible due to the risk of postoperative worsening of intestinal function and the need for subsequent reoperation 2
Nutritional support with enteral nutrition (EN) is recommended as the first line of treatment for patients unable to meet energy needs with oral nutrition, with home parenteral nutrition (HPN) considered only when oral or enteral nutrition is clearly inadequate 1, 8, 2